semaglutide and ibs-c Semaglutide-Induced Small Bowel Pseudo-Obstruction Ileitis in a Patient With Type 2 Diabetes: A Case Report Managing Gastroparesis and SIBO associated

Many retinal changes occur without noticeable symptoms, which is why regular screening is vital

Remember that the goal of GLP-1 therapy is sustainable, long-term weight lossnot perfection

Non-obese patients with metabolic syndrome, family history of type 2 diabetes, or documented cardiovascular disease often benefit from GLP-1 therapy as part of comprehensive risk reduction strategies

Many people also report that it quiets food chatter or helps them worry less about what or when they will eat next

Early clinical data have generated significant scientific interest, particularly for the treatment of obesity and type 2 diabetes